AEB 1102

Drug Profile

AEB 1102

Alternative Names: AEB1102; AERase; Co-ArgI-PEG - Aeglea Biotherapeutics; Co-ArgI-PEG modified human arginase I - Aeglea Biotherapeutics; Optimised human arginase I - Aeglea Biotherapeutics; PEG-arginase - Aeglea Biotherapeutics; Pegarginase - Aeglea Biotherapeutics; Pegzilarginase

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Aeglea Biotherapeutics
  • Class Antineoplastics; Polyethylene glycols; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Inborn urea cycle disorders
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 17 Jan 2017 Initial efficacy data from a phase I trial in Inborn urea cycle disorders released by Aeglea BioTherapeutics
  • 08 Nov 2016 Pharmacodynamics data from a preclinical trial in Solid tumours released by Aeglea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top